Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
Hexaware Achieves AWS Premier Tier Status in the Amazon Web Services Partner Network
MUMBAI, India and ISELIN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Hexaware…
Sirona Biochem Update to Shareholders on Financial Status and Operations
August 01, 2025 16:30 ET | Source: Sirona Biochem Corp. VANCOUVER, British…
DP WORLD DELIVERS SAILGP FLEET TO PORT TARGETING NET-ZERO STATUS
DP World, SailGP's Global Smart Logistics Partner, delivers racing fleet into Port…
WIKATI Accredited with ICEF Agency Status
HYDERABAD, India, July 8, 2025 /PRNewswire/ -- WIKATI Education Services LLC has…
